

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application #	10/562,396
Confirmation #	8440
Filing Date	April 14, 2006
First Inventor	SCHWARTZ
Art Unit	1615
Examiner	

Sheet 1 of 2

Docket # P08824US00/BAS

U.S. PATENT DOCUMENTS

Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-2004/220225 (Equivalent of EP 0 982 300 and EP 1 428 820)	04-11-2004	SCHWARTZ ET AL	
	US-6,248,765	06-19-2001	SCHUNACK ET AL	
	US-2002/065278	05-30-2002	CARRUTHERS ET AL	
	US-2003/096808	05-22-2003	MILLER JON M.	

FOREIGN PATENT DOCUMENTS

Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Translation

NON PATENT LITERATURE DOCUMENTS

Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Translation
	VOHORA D. ET AL; "Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy." April 2001; pgs 735-741, vol. 68, no. 4; PHARMACOLOGY, BIOCHEMISTRY, AND BEHAVIOR; United States	
	STARK H. ET AL; "Developments of Histamine H3-receptor Antagonists" 1996, pgs. 507-520; vol. 21, no. 5, DRUGS OF THE FUTURE, Barcelona, Spain	
	MONTI J. M. ET AL; "Effects of selective activation or blockade of the histamine H3 receptor on sleep and wakefulness." December 3, 1991, pgs. 283 - 287; vol. 205, no. 3, EUROPEAN JOURNAL OF PHARMACOLOGY; Netherlands	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application #	10/562,396
	Confirmation #	8440
	Filing Date	April 14, 2006
	First Inventor	SCHWARTZ
	Art Unit	1615
	Examiner	
Sheet 2 of 2	Docket #	P08824US00/BAS

NON PATENT LITERATURE DOCUMENTS		
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Trans-lation
	MIYAZAKI S. ET AL; "Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice." 1995; pgs. 2137-2144; vol. 57, no. 23; LIFE SCIENCES, England	
	GANELLIN C. R. ET AL; "synthesis of potent non-imidazole histamine H3-receptor antagonists" 1998; pgs. 395-404; vol. 331, no. 12; ARCHIV DER PHARMAZIE; Germany	
	LIEDTKE ET AL; "Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists." Jan. 2003; pgs. 43-50; vol. 367, no. 1; NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY; Germany	
	MEIER ET AL; "Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists" June 2001; pgs. 249-259; vol. 13, no. 3; EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES	
	SHADBOLT ET AL; "Some Aryloxyalkylamines, N-Arylethylenediamines and Related Compounds as Anorectic Agents" 1971; pgs. 836-842; vol. 14, no. 9; JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY; Washington D.C.	

Examiner Signature	/Sarah Pihonak/	Date Considered	07/06/2009
--------------------	-----------------	-----------------	------------

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.